An Intervention Study for Adults with Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors

Proof-of-Activity Study with Orticumab in Subjects with Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors

dry skin with rash

 

AGE: 30 years and older
SEX AT BIRTH: All
TYPE: Interventional Drug Study
CONDITION: Plaque psoriasis
HEALTHY PARTICIPANTS: No
LOCATION: University Hospitals Cleveland Medical Center

Learn More About This Research Study

For more information, please contact study coordinator, Dr. Emma Larson at 216-844-5728 or complete the form below.

Study Purpose

The purpose of this research study is to test an experimental drug called Orticumab, a monocolonal antibody, to assess the safety and tolerability in subjects with moderate-to-severe psoriasis and cardiometabolic risk factors (obesity, high low-density lipoprotein (also called “LDL” or “bad” cholesterol), high blood fat (triglycerides), low high-density lipoprotein (also called “HDL” or “good” cholesterol), high blood pressure, diabetes, smoking tobacco).

Who Can Participate

Participants 30 years and older diagnosed with plaque psoriasis, have a BMI equal to or greater than 30 and whose LDL is greater than 100 mg/dL at the time of screening may be eligible for this study.

Request More Information

To learn more about this study, please fill out the form below to request more information.

XXX-XXX-XXXX

STUDY ID#

  • STUDY20210910